When researchers treated hepatoma cells with EGCG, VEGFR-2 expression markedly decreased in a time- and dose-dependent manner, implying EGCG may inhibit HCC cell growth by targeting VEGF-VEGFR axis (Shirakami et al., 2009). This evidence concerns the gene KDR and hepatocellular carcinoma.